Background: COVID-19 is a pandemic disease caused by SARS-CoV-2, which is an RNA virus similar to HCV in the replication process. Sofosbuvir/ledipasvir is an approved drug by the FDA to treat HCV infection. This study investigates the efficacy of Sofosbuvir/ledipasvir as a treatment for patients with moderate COVID-19 infection.. Methods: This is a single-blinded parallel-randomized controlled trial. The participants were randomized equally into the intervention group received Sofosbuvir/ledipasvir (S.L. group), and the control group received Oseltamivir, Hydroxychloroquine, and Azithromycin (OCH group). The primary outcomes were the cure rate over time and the incidence of serious adverse events. The secondary outcomes included the laboratory findings. Results: Two hundred and fifty patients were divided equally into each group. Both groups were similar regarding gender, but age was higher in the S.L. group (p=0.001). In the S.L. group, 89 (71.2%) patients were cured, while only 51 (40.8%) patients were cured in the OCH group. The cure rate was significantly higher in the S.L. group (RR=1.75, p<0.001). Kaplan-Meir plot showed a considerably higher cure over time in the S.L. group (Log-rank test, p=0.032). There were no deaths in the S.L. group, but there were six deaths (4.8%) in the OCH group (RR=0.08, p=0.013). Seven patients (5.6%) in the S.L. group and six patients (4.8%) in the OCH group were admitted to ICU (RR=1.17, P=0.776). There was no significant difference between treatment groups regarding Total Leukocyte Count, Neutrophils count, Lymph, Alanine transaminase, and Urea. Conclusion: Sofosbuvir/ledipasvir is suggestive of being effective in treating patients with moderate COVID-19 infection. Further studies are needed to compare Sofosbuvir/ledipasvir with the new treatment protocols.
This study is a cross sectional study conducted in Tropical Medicine Department, Ain Shams University hospitals and included ninety Egyptian patients with HCV related chronic liver disease (diagnosed on clinical, laboratory and ultrasonography basis), divided into three groups according to Child Pugh scoring system to classify their liver cirrhosis stage into three equal groups (n=30 in each) as following: early (Child A), moderate (Child B) and severe liver cirrhosis (Child Abstract Introduction: Over the past years, the role of nutrition as one of the most important factors that can influence overall mortality and morbidity in end stage liver disease (ESLD) has been well understood and appreciated, Our study aimed at assessment the dietary intake of the Egyptian cirrhotic patients (due to hepatitis C virus).Patients and methods: Ninety patients were included in the study were divided into three groups according their liver condition according to Child Pugh scoring system (thirty patients of each child class) and all were subjected to careful history (including medical dietary advice, appetite assessment) and thorough dietary history (including 24 hour recall and food frequency). Results:We found Predominance of unsafe intake in calories, calcium, magnesium, potassium and zinc, which was more overt in advanced patients. While predominance of over consumption in protein, sodium, iron, selenium and copper, more in Child A group patients. Using food frequency method, we found that with progress of liver disease, there are fewer variations with more restrictions and limitations regarding the intake. Conclusion:Dietary assessment is an important part of the assessment of liver disease patients and offers helpful nutrition interventions to ensure satisfactory nutrient intake and improve the overall clinical outcome of the patient.
Background:The hepatitis C virus (HCV) may be an important explanation for hepatic pathology, cirrhosis, and hepatocellular carcinoma. The aim of the study was to assess the liver stiffness before and after oral antiviral medication in chronic viral hepatitis c patients attending Zagazig University Hospitals. Methods: This study included forty three Egyptian patients with HCV infection diagnosed by HCV RNA real time quantitative PCR whose ages were ranged from 29-71 , All patients took anti-viral treatment according to the rules of the committee responsible for hepatitis c virus control in Egypt. Treatment regimens included: Sofosbuvir, daclatasvir and ribavirin (RBV). The patients were collected and followed up in the period between April 2017 and August 2018. , radiological tool liver transient elastography (TE) and laboratory tests APRI, FIB4 test were done for all patients. Results: There were improvements in liver stiffness measurements,APRI,FIB4 test hemoglobin, fasting blood sugar , platelets count, and ALT, AST levels in patients who achieved a 48-week sustained infectious agent response. The failure to achieve improvement within the level of liver stiffness was related to treatment failure. Conclusions: Treatment with sofosbuvir drug regimen makes significant decrease in liver stiffness measurements and fibrosis indices.
COVID-19 is a pandemic disease caused by SARS-CoV-2, which is an RNA virus similar to the hepatitis C virus (HCV) in the replication process. Sofosbuvir/ledipasvir is an approved drug to treat HCV infection. This study investigates the efficacy of Sofosbuvir/ledipasvir as a treatment for patients with moderate COVID-19 infection. This is a single-blinded parallel-randomized controlled trial. The participants were randomized equally into the intervention group that received Sofosbuvir/ledipasvir (S.L. group), and the control group received Oseltamivir, Hydroxychloroquine, and Azithromycin (OCH group). The primary outcomes were the cure rate over time and the incidence of serious adverse events. The secondary outcomes included the laboratory findings. 250 patients were divided equally into each group. Both groups were similar regarding gender, but age was higher in the S.L. group (p=0.001). In the S.L. group, 89 (71.2%) patients were cured, while only 51 (40.8%) patients were cured in the OCH group. The cure rate was significantly higher in the S.L. group (RR=1.75, p<0.001). Kaplan-Meir plot showed a considerably higher cure over time in the S.L. group (Log-rank test, p=0.032). There were no deaths in the S.L. group, but there were six deaths (4.8%) in the OCH group (RR=0.08, p=0.013). Seven patients (5.6%) in the S.L. group and six patients (4.8%) in the OCH group were admitted to the intensive care unit (ICU) (RR=1.17, P=0.776). There were no significant differences between treatment groups regarding total leukocyte and neutrophils count, lymph, and urea. Sofosbuvir/ledipasvir is suggestive of being effective in treating patients with moderate COVID-19 infection. Further studies are needed to compare Sofosbuvir/ledipasvir with new treatment protocols.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.